Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-122 vs Krytantek Ofteno in Healthy Subjects
NCT03966365Phase 1Completed
- Sponsor
- Laboratorios Sophia
- Start
- May 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dorzolamide + timolol + brimonidine in Primary Open Angle Glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Laboratorios Sophia. Primary endpoints: Number of Adverse Events at 14 days and Eye Comfort Index at Day 8. Started May 2019; status: completed.
02
Drugs
dorzolamide + timolol + brimonidine
03
Conditions
Primary Open Angle Glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03966365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03966365.